Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma

@inproceedings{Jeannot2016SynergisticAO,
  title={Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma},
  author={Victor Jeannot and Benoit Busser and Laetitia Vanwonterghem and Sophie Michallet and Sana Ferroudj and Murat Cokol and Jean-Luc Coll and Mehmet Fatih Ozturk and Amandine Hurbin},
  booktitle={OncoTargets and therapy},
  year={2016}
}
Development of drug resistance limits the efficacy of targeted therapies. Alternative approaches using different combinations of therapeutic agents to inhibit several pathways could be a more effective strategy for treating cancer. The effects of the approved epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (gefitinib) or a multi-targeted kinase inhibitor (sorafenib) in combination with a histone deacetylase inhibitor (vorinostat) on cell proliferation, cell cycle distribution… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 50 references

The BATTLE trial: personalizing therapy for lung cancer.

Cancer discovery • 2011
View 6 Excerpts
Highly Influenced

Sorafenib in Advanced Hepatocellular Carcinoma

The New England journal of medicine • 2008
View 7 Excerpts
Highly Influenced

DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2015
View 1 Excerpt

( NSCLC ) patients with epidermal growth factor receptor ( EGFR ) mutations after erlotinib progression

SE Witta, RM Jotte, K Konduri
2014